Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Current ratio | 3.86 | 3.05 | 2.63 | 3.60 | 3.85 | |
Quick ratio | 2.57 | 2.13 | 1.67 | 2.24 | 2.34 | |
Cash ratio | 1.94 | 1.66 | 1.07 | 1.39 | 1.43 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
Liquidity ratio | Description | The company |
---|---|---|
Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Zoetis Inc. current ratio improved from 2019 to 2020 and from 2020 to 2021. |
Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Zoetis Inc. quick ratio improved from 2019 to 2020 and from 2020 to 2021. |
Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Zoetis Inc. cash ratio improved from 2019 to 2020 and from 2020 to 2021. |
Current Ratio
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Current assets | 6,930) | 6,611) | 4,748) | 4,399) | 4,217) | |
Current liabilities | 1,797) | 2,170) | 1,806) | 1,223) | 1,094) | |
Liquidity Ratio | ||||||
Current ratio1 | 3.86 | 3.05 | 2.63 | 3.60 | 3.85 | |
Benchmarks | ||||||
Current Ratio, Competitors2 | ||||||
AbbVie Inc. | 0.79 | 0.84 | 3.18 | — | — | |
Amgen Inc. | 1.59 | 1.81 | 1.44 | — | — | |
Bristol-Myers Squibb Co. | 1.52 | 1.58 | 1.60 | — | — | |
Eli Lilly & Co. | 1.23 | 1.40 | 1.16 | — | — | |
Gilead Sciences Inc. | 1.27 | 1.40 | 3.10 | — | — | |
Johnson & Johnson | 1.35 | 1.21 | 1.26 | — | — | |
Merck & Co. Inc. | 1.27 | 1.02 | 1.24 | — | — | |
Pfizer Inc. | 1.40 | 1.35 | 0.88 | — | — | |
Regeneron Pharmaceuticals Inc. | 3.56 | 3.63 | 3.67 | — | — | |
Thermo Fisher Scientific Inc. | 1.50 | 2.13 | 1.92 | — | — | |
Vertex Pharmaceuticals Inc. | 4.46 | 4.33 | 3.61 | — | — | |
Current Ratio, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | 1.36 | 1.36 | 1.56 | — | — | |
Current Ratio, Industry | ||||||
Health Care | 1.22 | 1.22 | 1.34 | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Current ratio = Current assets ÷ Current liabilities
= 6,930 ÷ 1,797 = 3.86
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Zoetis Inc. current ratio improved from 2019 to 2020 and from 2020 to 2021. |
Quick Ratio
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Cash and cash equivalents | 3,485) | 3,604) | 1,934) | 1,602) | 1,564) | |
Short-term investments | —) | —) | —) | 99) | —) | |
Accounts receivable, less allowance for doubtful accounts | 1,133) | 1,013) | 1,086) | 1,036) | 998) | |
Total quick assets | 4,618) | 4,617) | 3,020) | 2,737) | 2,562) | |
Current liabilities | 1,797) | 2,170) | 1,806) | 1,223) | 1,094) | |
Liquidity Ratio | ||||||
Quick ratio1 | 2.57 | 2.13 | 1.67 | 2.24 | 2.34 | |
Benchmarks | ||||||
Quick Ratio, Competitors2 | ||||||
AbbVie Inc. | 0.56 | 0.60 | 2.91 | — | — | |
Amgen Inc. | 1.06 | 1.30 | 1.01 | — | — | |
Bristol-Myers Squibb Co. | 1.20 | 1.28 | 1.26 | — | — | |
Eli Lilly & Co. | 0.80 | 0.85 | 0.68 | — | — | |
Gilead Sciences Inc. | 0.95 | 1.08 | 2.86 | — | — | |
Johnson & Johnson | 1.04 | 0.91 | 0.94 | — | — | |
Merck & Co. Inc. | 0.73 | 0.58 | 0.78 | — | — | |
Pfizer Inc. | 1.00 | 0.78 | 0.50 | — | — | |
Regeneron Pharmaceuticals Inc. | 2.98 | 2.86 | 2.81 | — | — | |
Thermo Fisher Scientific Inc. | 1.00 | 1.63 | 1.19 | — | — | |
Vertex Pharmaceuticals Inc. | 4.04 | 4.02 | 3.33 | — | — | |
Quick Ratio, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | 0.98 | 0.96 | 1.18 | — | — | |
Quick Ratio, Industry | ||||||
Health Care | 0.90 | 0.91 | 1.01 | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 4,618 ÷ 1,797 = 2.57
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Zoetis Inc. quick ratio improved from 2019 to 2020 and from 2020 to 2021. |
Cash Ratio
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Cash and cash equivalents | 3,485) | 3,604) | 1,934) | 1,602) | 1,564) | |
Short-term investments | —) | —) | —) | 99) | —) | |
Total cash assets | 3,485) | 3,604) | 1,934) | 1,701) | 1,564) | |
Current liabilities | 1,797) | 2,170) | 1,806) | 1,223) | 1,094) | |
Liquidity Ratio | ||||||
Cash ratio1 | 1.94 | 1.66 | 1.07 | 1.39 | 1.43 | |
Benchmarks | ||||||
Cash Ratio, Competitors2 | ||||||
AbbVie Inc. | 0.28 | 0.30 | 2.56 | — | — | |
Amgen Inc. | 0.66 | 0.91 | 0.69 | — | — | |
Bristol-Myers Squibb Co. | 0.78 | 0.83 | 0.84 | — | — | |
Eli Lilly & Co. | 0.26 | 0.29 | 0.21 | — | — | |
Gilead Sciences Inc. | 0.56 | 0.65 | 2.50 | — | — | |
Johnson & Johnson | 0.70 | 0.59 | 0.54 | — | — | |
Merck & Co. Inc. | 0.34 | 0.30 | 0.47 | — | — | |
Pfizer Inc. | 0.73 | 0.47 | 0.26 | — | — | |
Regeneron Pharmaceuticals Inc. | 1.45 | 1.33 | 1.53 | — | — | |
Thermo Fisher Scientific Inc. | 0.33 | 1.00 | 0.39 | — | — | |
Vertex Pharmaceuticals Inc. | 3.51 | 3.55 | 2.85 | — | — | |
Cash Ratio, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | 0.59 | 0.58 | 0.81 | — | — | |
Cash Ratio, Industry | ||||||
Health Care | 0.52 | 0.54 | 0.64 | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 3,485 ÷ 1,797 = 1.94
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Zoetis Inc. cash ratio improved from 2019 to 2020 and from 2020 to 2021. |